- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07603700
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism (STRATEGY-PE)
Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Background: Acute pulmonary embolism (PE) is a severe manifestation of venous thromboembolism (VTE). Intermediate-high risk PE accounts for 20-30% of all PE cases with significant mortality driven by right ventricular (RV) dysfunction. Current guidelines recommend anticoagulation for all, with thrombolysis or mechanical thrombectomy as rescue or alternative therapies. However, there is significant heterogeneity in real-world treatment selection and a lack of head-to-head comparative evidence among the three strategies in complex real-world populations.
Objective: To compare the 30-day and 90-day all-cause mortality and 48-hour RV/LV ratio improvement rate among three treatment strategies (Anticoagulation, Thrombolysis, Mechanical Thrombectomy) in patients with intermediate-high risk acute PE.
Design: This is a prospective, multicenter, non-randomized, pragmatic cohort study. Treatment allocation is based on routine clinical decision-making (natural allocation) without investigator intervention. Advanced statistical methods (Propensity Score Matching/Weighting, Instrumental Variable analysis) will be used to control for confounding factors.
Participants: 1,300 patients with confirmed acute intermediate-high risk PE (RV/LV ratio ≥0.9 and elevated cardiac biomarkers, hemodynamically stable). There are no age limits to reflect real-world diversity.
Interventions/Exposures:
- Anticoagulation (AC): Standard anticoagulant therapy (LMWH, DOAC, UFH, or Warfarin).
- Thrombolysis (TL): Systemic thrombolysis or Catheter-Directed Thrombolysis (CDT) using agents like Urokinase, Alteplase, etc.
- Mechanical Thrombectomy (MT): Mechanical removal of thrombus using FDA/NMPA approved devices (e.g., Indigo, FlowTriever, Acoscream), with or without adjunctive anticoagulation/thrombolysis.
Outcomes:
- Primary: 30-day and 90-day all-cause mortality; 48-hour RV/LV ratio improvement rate (≥15% reduction).
- Secondary: Clinical deterioration, major bleeding (ISTH/GUSTO/BARC), functional status (6MWT, NYHA, PVFS), quality of life (PEmb-QoL, EQ-5D-5L), PE recurrence, and healthcare resource utilization.
Follow-up: Patients will be followed at 48 hours, 7 days, 30 days, and 90 days.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: he xu Dr, doctor
- Telefonnummer: +86 153 6611 0045
- E-post: kilogram@163.com
Studieorter
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210006
- Nanjing First Hospital
-
Kontakt:
- Interventional Vascular Department Director, doctor
- Telefonnummer: +86-25-52271000
- E-post: kilogram@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Age unlimited (reflecting real-world population).
- Symptom duration of acute PE ≤ 14 days.
- Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.
- Defined as Intermediate-High Risk PE meeting all of the following:
- RV/LV ratio ≥ 0.9 (by CT or Echocardiography).
- Elevated cardiac biomarkers (Troponin > 99th percentile or BNP > 100 pg/mL).
- Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).
- Able to provide informed consent and complete follow-up.
Exclusion Criteria:
- Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.
- Unable to obtain baseline or follow-up CTPA imaging.
- (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Anticoagulation Cohort
Patients receiving standard anticoagulation therapy alone without thrombolysis or mechanical thrombectomy.
|
Low Molecular Weight Heparin (LMWH), Direct Oral Anticoagulants (DOAC), Unfractionated Heparin (UFH), or Warfarin according to guideline-standard regimens.
Andra namn:
|
|
Thrombolysis Cohort
Patients receiving systemic thrombolysis or catheter-directed thrombolysis.
|
Any FDA/NMPA approved mechanical thrombectomy device (e.g., Indigo, FlowTriever, Acoscream) used for clot removal.
Andra namn:
|
|
Mechanical Thrombectomy Cohort
Patients undergoing mechanical thrombectomy procedures using percutaneous devices.
|
Urokinase, Pro-urokinase, Alteplase, or Tenecteplase administered systemically or via catheter.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
All-Cause Mortality at 30 Days
Tidsram: 30 days
|
The percentage of participants who die from any cause within 30 days of enrollment.
|
30 days
|
|
All-Cause Mortality at 90 Days
Tidsram: 90 days
|
The percentage of participants who die from any cause within 90 days of enrollment.
|
90 days
|
|
Right Ventricular to Left Ventricular (RV/LV) Ratio Improvement Rate at 48 Hours
Tidsram: 48 hours ± 6 hours
|
The proportion of participants with a reduction in RV/LV ratio ≥15% from baseline measured by CTPA or Echocardiography.
|
48 hours ± 6 hours
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Major Bleeding Events
Tidsram: 48 hours, 7 days, 30 days, 90 days
|
Incidence of major bleeding defined by ISTH, GUSTO, or BARC criteria (including intracranial hemorrhage).
|
48 hours, 7 days, 30 days, 90 days
|
|
Clinical Deterioration
Tidsram: 48 hours, 7 days
|
Composite of hemodynamic instability, need for rescue therapy (escalation to thrombolysis/MT/ECMO), intubation, or PE-related death.
|
48 hours, 7 days
|
|
6-Minute Walk Test (6MWT) Distance
Tidsram: 30 days, 90 days
|
Change in walking distance from baseline (estimated) to follow-up.
Minimal Clinically Important Difference (MCID) ≥30 meters.
|
30 days, 90 days
|
|
Post-VTE Functional Status (PVFS) Score
Tidsram: 30 days, 90 days
|
Assessment of functional limitation due to VTE (Scale 0-5).
|
30 days, 90 days
|
|
Quality of Life (PEmb-QoL)
Tidsram: 90 days
|
The questionnaire consists of 9 questions containing 40 items, which are organized into 6 domains: Frequency of Complaints (FC): Assesses the frequency of respiratory and general symptoms (e.g., dyspnea, chest pain). Daily Activity Limitations (AL): Measures limitations in performing activities of daily living (ADL). Work-related Problems (WP): Evaluates difficulties in performing work or school duties. Social Limitations (SL): Assesses restrictions on social activities. Intensity of Complaints (IC): Measures the severity of pain and breathlessness. Emotional Complaints (EC): Captures anxiety, frustration, and fear related to the disease. |
90 days
|
|
Symptomatic PE Recurrence
Tidsram: 90 days
|
Confirmed recurrent PE via CTPA or V/Q scan.
|
90 days
|
|
ICU Length of Stay
Tidsram: From ICU admission to ICU discharge, assessed up to 30 days
|
Duration of intensive care unit stay during the index hospitalization
|
From ICU admission to ICU discharge, assessed up to 30 days
|
|
Total Hospital Length of Stay
Tidsram: From hospital admission to hospital discharge, assessed up to 90 days
|
Duration of index hospitalization from emergency department admission to hospital discharge
|
From hospital admission to hospital discharge, assessed up to 90 days
|
|
Total Medical Costs
Tidsram: Through 90 days
|
Direct medical costs incurred during index hospitalization and within 90 days of enrollment, including medications, procedures, and hospitalization
|
Through 90 days
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Biomarker Improvement (Troponin, BNP, D-Dimer)
Tidsram: 48 hours, 7 days
|
Percentage reduction in cardiac biomarkers and D-Dimer levels.
|
48 hours, 7 days
|
|
Daily Step Count
Tidsram: Continuous monitoring through 90 days
|
Average daily step count measured by smart band (e.g., Xiaomi/Huawei/Apple Watch) during the 90-day follow-up period.
Assessed as a continuous variable (steps/day) and correlated with 6-Minute Walk Test distance and Post-VTE Functional Status score.
|
Continuous monitoring through 90 days
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Luftvägssjukdomar
- Lungsjukdomar
- Embolism och trombos
- Emboli
- Tromboembolism
- Lungemboli
- Venös tromboembolism
- Molekylära mekanismer för farmakologisk verkan
- Fibrinmodulerande medel
- Aminosyror, peptider och proteiner
- Proteiner
- Svavelföreningar
- Organiska kemikalier
- Pyridiner
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Bensimidazol
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Pyraner
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Terapeutisk användning
- Kolhydrater
- Hydrolaser
- Enzymer
- Enzymer och koenzymer
- Blodproteiner
- Heparin, lågmolekylär vikt
- Glykosaminoglykaner
- Polysackarider
- Morfoliner
- Oxaziner
- Tiofener
- Kumarin
- Bensopyraner
- Endopeptidaser
- Peptidhydrolaser
- Serin endopeptidaser
- Serinproteaser
- Plasminogenaktivatorer
- Blodkoagulationsfaktorer
- Kardiovaskulär medel
- 4-hydroxikoumariner
- Vävnadsplasminogenaktivator
- Hematologiska medel
- Rivaroxaban
- Dabigatran
- Tenecteplas
- Enoxaparin
- Warfarin
- Heparin
- Antikoagulanter
- Fibrinolytiska medel
- apixaban
- edoxaban
- Urokinase-Type Plasminogen Activator
Andra studie-ID-nummer
- KY20260205-04
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .